The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Badiola, Nahuai ^a   Alcalde, Victor ^a   Pujol, Albert ^a,b   Münter, Lisa Marie ^c   Multhaup, Gerd ^c   Lleó, Alberto ^d   Coma, Mireia ^b   Soler López, Montserrat ^a   Aloy, Patrick ^a,e  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b Anaxomics Biotech   (Spain)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE 1; FLURBIPROFEN; GAMMA SECRETASE; LANSOPRAZOLE; MEPRIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; BRAIN LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DRUG TOXICITY; ENZYME ACTIVITY; HUMAN; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; TREATMENT RESPONSE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, KNOCKOUT; PROTON PUMPS;

EID: 84874764940     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058837     Document Type: Article

References (57)

1. Hardy J, Selkoe DJ, (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356.
2. Querfurth HW, LaFerla FM, (2010) Alzheimer's Disease. New England Journal of Medicine 362: 329-344.
3. Younkin SG, (1998) The role of Aβ42 in Alzheimer's disease. Journal of Physiology-Paris 92: 289-292.
4. Wiltfang J, Esselmann H, Bibl M, Smirnov A, Otto M, et al. (2002) Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. Journal of Neurochemistry 81: 481-496.
5. Meyer-Luehmann M, Stalder M, Herzig MC, Kaeser SA, Kohler E, et al. (2003) Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci 6: 370-377.
6. Spires-Jones TL, Meyer-Luehmann M, Osetek JD, Jones PB, Stern EA, et al. (2007) Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol 171: 1304-1311.
7. Ingelsson M, Fukumoto H, Newell KL, Growdon JH, Hedley-Whyte ET, et al. (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62: 925-931.
8. Gomez-Isla T, Hollister R, West H, Mui S, Growdon JH, et al. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol 41: 17-24.
9. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, et al. (2003) Alzheimer's disease-affected brain: Presence of oligomeric β ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proceedings of the National Academy of Sciences 100: 10417-10422.
10. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, et al. (1999) Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease. The American Journal of Pathology 155: 853-862.
11. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, et al. (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
12. Pitschke M, Prior R, Haupt M, Riesner D, (1998) Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat Med 4: 832-834.
13. Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, et al. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8: 79-84.
14. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 95: 6448-6453.
15. Walsh DM, Selkoe DJ, (2007) Aβ Oligomers - a decade of discovery. Journal of Neurochemistry 101: 1172-1184.
16. Shrestha BR, Vitolo OV, Joshi P, Lordkipanidze T, Shelanski M, et al. (2006) Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol Cell Neurosci 33: 274-282.
17. Haass C, Selkoe DJ, (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide. Nat Rev Mol Cell Biol 8: 101-112.
18. DaRocha-Souto B, Scotton TC, Coma M, Serrano-Pozo A, Hashimoto T, et al. (2011) Brain oligomeric beta-amyloid but not total amyloid plaque burden correlates with neuronal loss and astrocyte inflammatory response in amyloid precursor protein/tau transgenic mice. J Neuropathol Exp Neurol 70: 360-376.
19. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, et al. (2010) High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. The FASEB Journal 24: 2716-2726.
20. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, et al. (2008) Amyloid-[beta] protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
21. Wang-Dietrich L, Funke SA, Kühbach K, Wang K, Besmehn A, et al. (2013) The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease. Journal of Alzheimer's Disease.
22. Lleó A, Greenberg SM, Growdon JH, (2006) Current Pharmacotherapy for Alzheimer's Disease. Annual Review of Medicine 57: 513-533.
23. Mas J, Pujol A, Farrés J, Aloy P (2010) Methods and Systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data. Patent. United States of America.
24. Pujol A, Mosca R, Farres J, Aloy P, (2010) Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 31: 115-123.
25. Coma M, Pujol A, Gomis F, Oliva B, Lleó A, et al. (2011) New combination therapies for treating neurological disorders. Patent. United States of America.
26. Londong W, Barth H, Dammann HG, Hengels KJ, Kleinert R, et al. (1991) Dose-related healing of duodenal ulcer with the proton pump inhibitor lansoprazole. Aliment Pharmacol Ther 5: 245-254.
27. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, et al. (1989) Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. Journal of Pharmacology and Experimental Therapeutics 248: 806-815.
28. Arnold R, (1994) Safety of proton pump inhibitors: an overview. Aliment Pharmacol Ther 8 (Suppl 1): 65-70.
29. Lai K-C, Chu K-M, Hui W-M, Wong BC-Y, Hu WH-C, et al. (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. The American Journal of Medicine 118: 1271-1278.
30. Sheen E, Triadafilopoulos G, (2011) Adverse Effects of Long-Term Proton Pump Inhibitor Therapy. Digestive Diseases and Sciences 56: 931-950.
31. Xia W, Zhang J, Perez R, Koo EH, Selkoe DJ, (1997) Interaction between amyloid precursor protein and presenilins in mammalian cells: Implications for the pathogenesis of Alzheimer's disease. Proceedings of the National Academy of Sciences 94: 8208-8213.
32. Nakagawa S, Arai Y, Kishida T, Hiraoka N, Tsuchida S, et al. (2012) Lansoprazole Inhibits Nitric Oxide and Prostaglandin E2 Production in Murine Macrophage RAW 264.7 Cells. Inflammation 35: 1062-1068.
33. Damaj B (2009) Methods to inhibit tumor cell growth by using proton pump inhibitors. Patent. United States of America.
34. Schulz-Geske S, Erdmann K, Wong RJ, Stevenson DK, Schroder H, et al. (2009) Molecular mechanism and functional consequences of lansoprazole-mediated heme oxygenase-1 induction. World J Gastroenterol 15: 4392-4401.
35. Takagi T, Naito Y, Okada H, Ishii T, Mizushima K, et al. (2009) Lansoprazole, a Proton Pump Inhibitor, Mediates Anti-Inflammatory Effect in Gastric Mucosal Cells through the Induction of Heme Oxygenase-1 via Activation of NF-E2-Related Factor 2 and Oxidation of Kelch-Like ECH-Associating Protein 1. Journal of Pharmacology and Experimental Therapeutics 331: 255-264.
36. Tanigawa T, Watanabe T, Higuchi K, Machida H, Okazaki H, et al. (2009) Lansoprazole, a Proton Pump Inhibitor, Suppresses Production of Tumor Necrosis Factor-α and Interleukin-1β Induced by Lipopolysaccharide and Helicobacter Pylori Bacterial Components in Human Monocytic Cells via Inhibition of Activation of Nuclear Factor-κB and Extracellular Signal-Regulated Kinase. Journal of Clinical Biochemistry and Nutrition 45: 86-92.
37. Querfurth HW, Selkoe DJ, (1994) Calcium ionophore increases amyloid beta peptide production by cultured cells. Biochemistry 33: 4550-4561.
38. Querfurth HW, Jiang J, Geiger JD, Selkoe DJ (1997) Caffeine Stimulates Amyloid β-Peptide Release from β-Amyloid Precursor Protein-Transfected HEK293 Cells. Blackwell Science Ltd. 1580-1591.
39. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, et al. (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11: 545-550.
40. Moreira Dias L, (2009) Pantoprazole: A Proton Pump Inhibitor. Clinical Drug Investigation 29: 3-12.
41. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, et al. (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212-216.
42. Abdul-Hay SO, Edirisinghe P, Thatcher GRJ, (2009) Selective modulation of amyloid-β peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Aβ levels. Journal of Neurochemistry 111: 683-695.
43. Narlawar R, Perez Revuelta BI, Baumann K, Schubenel R, Haass C, et al. (2007) N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated gamma-secretase. Bioorg Med Chem Lett 17: 176-182.
44. Geerts H, (2007) Drug evaluation: (R)-flurbiprofen-an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. IDrugs 10: 121-133.
45. Morihara T, Chu T, Ubeda O, Beech W, Cole GM, (2002) Selective inhibition of Aβ42 production by NSAID R-enantiomers. Journal of Neurochemistry 83: 1009-1012.
46. Pilotto A, Sancarlo D, Addante F, Scarcelli C, Franceschi M, (2009) Non-steroidal anti-inflammatory drug use in the elderly. Surg Oncol 19: 167-172.
47. Lazzaroni M, Gabriele Bianchi P, (2009) Management of NSAID-Induced Gastrointestinal Toxicity: Focus on Proton Pump Inhibitors. Drugs 69: 51-69.
48. Vonkeman H, Fernandes R, van der Palen J, van Roon E, van de Laar M, (2007) Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case-control study. Arthritis Research & Therapy 9: R52.
49. Lleo A, Galea E, Sastre M, (2007) Molecular targets of non-steroidal anti-inflammatory drugs in neurodegenerative diseases. Cell Mol Life Sci 64: 1403-1418.
50. Richter L, Munter L-M, Ness J, Hildebrand PW, Dasari M, et al. (2010) Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proceedings of the National Academy of Sciences 107: 14597-14602.
51. Li Y, Zhou W, Tong Y, He G, Song W, (2006) Control of APP processing and Aβ generation level by BACE1 enzymatic activity and transcription. The FASEB Journal 20: 285-292.
52. Bien J, Jefferson T, Causevic M, Jumpertz T, Muenter L, et al. (2012) The metalloprotease meprin beta generates amino terminal truncated Abeta-peptide species. J Biol Chem.
53. Rojo LE, Alzate-Morales J, Saavedra IN, Davies P, Maccioni RB, (2010) Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease 19: 573-589.
54. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421.
55. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. The FASEB Journal 22: 659-661.
56. Pospai D, Cadiot G, Forestier S, Ruszniewski P, Coste T, et al. (1998) [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment]. Gastroenterol Clin Biol 22: 801-808.
57. Parsons C, Johnston S, Mathie E, Baron N, Machen I, et al. (2012) Potentially Inappropriate Prescribing in Older People with Dementia in Care Homes: A Retrospective Analysis. Drugs & Aging 29: 143-155.